Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Allergy and Asthma Associates of Southern California

Neither a doctor nor a teaching hospital

Research payments

$392,641

83 payments

Through program year 2025, Allergy and Asthma Associates of Southern California is reported as receiving $392,641 in research payments, across 83 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $37,699 6
2024 Research $47,115 17
2023 Research $45,320 3
2022 Research $72,865 10
2021 Research $127,111 23
2020 Research $27,152 16
2019 Research $35,380 8

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $124,568 17 payments
  2. AstraZeneca UK Limited $104,653 7 payments
  3. Aimmune Therapeutics, Inc. $56,086 20 payments
  4. AbbVie, Inc. $42,426 23 payments
  5. Novartis Pharmaceuticals Corporation $30,193 4 payments
  6. Sanofi US Services Inc. $18,343 5 payments
  7. GlaxoSmithKline, LLC. $13,648 3 payments
  8. AstraZeneca AB $1,569 2 payments
  9. E.R. Squibb & Sons, L.L.C. $1,095 1 payment
  10. Merck Sharp & Dohme Corporation $61 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria $104,653 7 payments
  2. A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma $55,645 6 payments
  3. A Multicenter, Open-Label, Long-Term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study $52,453 13 payments
  4. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $31,029 4 payments
  5. a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA $25,937 2 payments
  6. An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Tolerability of Lou064 in Eligible Subjects With Csu Who Have Participated in Preceding Studies With Lou064 $22,928 2 payments
  7. M16-045 $18,213 10 payments
  8. A Phase 3, 24-Week, Randomized, Double-Blind, Parallel-Group Bayesian $13,648 3 payments
  9. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $11,549 7 payments
  10. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis $10,300 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record